Product Description
PCS 3117 is an oral, anticancer agent being developed to treat metastatic pancreatic, biliary and other cancers. PCS3117 is an analog of the endogenous nucleoside, Cytidine, and an analog of the cancer drug gemcitabine. (Sourced from: https://www.processapharmaceuticals.com/product-pipeline/pcs3117#:~:text=PCS%203117%20is%20an%20oral,of%20the%20cancer%20drug%20gemcitabine.)
Mechanisms of Action: DNA Synthesis Inhibitor,RNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Processa Pharmaceuticals
Company Location: HANOVER MD 21076
Company CEO: David Young
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|